IceCure Medical Ltd (ICCM)
| Market Cap | 12.51M -79.3% |
| Revenue (ttm) | 3.57M +8.9% |
| Net Income | -15.74M |
| EPS | -6.99 |
| Shares Out | 3.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,297 |
| Open | 3.610 |
| Previous Close | 3.660 |
| Day's Range | 3.500 - 3.650 |
| 52-Week Range | 2.120 - 42.000 |
| Beta | 1.54 |
| Analysts | Strong Buy |
| Price Target | 30.50 (+735.62%) |
| Earnings Date | Aug 12, 2026 |
About ICCM
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncolo... [Read more]
Financial Performance
In 2025, IceCure Medical's revenue was $3.38 million, an increase of 2.67% compared to the previous year's $3.29 million. Losses were -$15.06 million, -1.70% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ICCM stock is "Strong Buy." The 12-month stock price target is $30.5, which is an increase of 735.62% from the latest price.
News
IceCure Medical expands U.S. commercial team for ProSense cryoablation
IceCure Medical (ICCM) announced the expansion of its United States sales and marketing teams. In response to demand from leading hospitals and physicians across the country, the company has strengthe...
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
CAESAREA, Israel, July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation ...
IceCure Medical Slides: Investor presentation
IceCure Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
IceCure Medical highlights expanding commercial adoption of ProSense
IceCure Medical (ICCM) highlighted the growing international interest in its ProSense system in Brazil at the Simposio de Radiologia Intervencionista em Oncologia. “IceCure’s ProSense(TM) holds Agenci...
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cancer ...
IceCure Medical registers to sell 5.5M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.5M ordinary shares. The company is not selling any shares under…
IceCure Medical regains compliance with Nasdaq minimum bid price requirement
IceCure Medical (ICCM) received written notice from Nasdaq indicating that the company has regained compliance with the minimum bid price requirement which requires listed securities to maintain a min...
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Medical Registration statement: Registration filing
IceCure Medical filed a registration statement on June 25, 2026, providing details about a securities offering with the SEC.
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
Published in the International Journal of Surgery, globally ranked in the top three among surgery journals , the article highlights strong clinical outcomes with ProSense® cryoablation and describes ...
Icecure Medical Ltd trading resumes
09:55 EDT Icecure Medical (ICCM) Ltd trading resumes
Icecure Medical Ltd trading halted, volatility trading pause
09:45 EDT Icecure Medical (ICCM) Ltd trading halted, volatility trading pause
Why Is IceCure Medical Stock (ICCM) Up Today?
IceCure Medical stock was up alongside new medical device progress and positive analyst comments.
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Medical business ‘moving in the right direction,’ says Brookline
Brookline tells investors in a research note that IceCure Medical’s (ICCM) disclosure of a 70% boost in the U.S. active commercial install base of ProSense for breast cancer cryoablation is…
IceCure Medical reports increase in ProSense use for breast cancer cryoablation
IceCure Medical (ICCM) reported a 70% increase in its U.S. active commercial install base of ProSense for breast cancer cryoablation following FDA marketing authorization in October 2025, reflecting a...
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences co...
Icecure Medical Ltd trading halted, news pending
19:50 EDT Icecure Medical (ICCM) Ltd trading halted, news pending
IceCure Medical implements 1-for-30 reverse share split for Nasdaq compliance
IceCure Medical (ICCM) intends to effect a one-for-thirty reverse split of the company’s ordinary shares, no par value per share, as part of its proactive efforts to regain compliance with…
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (the "Company" or "IceCure" or ...
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-f...
IceCure Medical price target lowered to $1 from $3 at Maxim
Maxim lowered the firm’s price target on IceCure Medical (ICCM) to $1 from $3 and keeps a Buy rating on the shares. The company’s Q1 loss per share was slightly…
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares CAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or th...
IceCure Medical reports Q1 EPS (6c) vs. (6c) last year
Reports Q1 revenue $911K, consensus $1.34M. “We are off to an incredibly strong start to 2026 and we are highly encouraged by the growing momentum we are experiencing in the…
IceCure Medical Earnings Call Transcript: Q1 2026
Revenue grew 26% year-over-year in Q1 2026, with strong U.S. and North American performance. FDA clearance for low-risk breast cancer has accelerated adoption, expanded the active account base, and driven global interest, with continued growth and commercial expansion expected.